Salivary duct carcinoma

Summary

Salivary duct carcinoma (MONDO:0044915) is a cancer and 6 clinical trials. Top therapeutic interventions include dutasteride, trastuzumab, and rimiducid. A subtype of salivary gland carcinoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Clinical trials: 6

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	salivary duct carcinoma
Mondo ID	MONDO:0044915
NCIT	C5904
UMLS	C1301194
MedGen	220969
GARD	0027981
Anatomy (UBERON)	UBERON:0001837
Is cancer (heuristic)	yes

Also known as: carcinoma of duct of salivary gland · carcinoma of salivary duct · carcinoma of the salivary duct · duct of salivary gland carcinoma · high grade salivary duct carcinoma · salivary duct carcinoma

Data availability: 1 cell line.

Disease family

This is a subtype of salivary gland carcinoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › digestive system disorder › digestive system cancer › oral cavity cancer › salivary gland cancer › salivary gland carcinoma › salivary duct carcinoma

Related subtypes (12): salivary gland adenoid cystic carcinoma, major salivary gland carcinoma, salivary gland basal cell adenocarcinoma, salivary gland carcinoma ex pleomorphic adenoma, salivary gland large cell carcinoma, salivary gland small cell carcinoma, salivary gland epithelial myoepithelial carcinoma, salivary gland mucoepidermoid carcinoma, salivary gland squamous cell carcinoma, minor salivary gland carcinoma, salivary gland mucinous adenocarcinoma, mammary analog secretory carcinoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 6.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	3
Not specified	2
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05513365	PHASE2	RECRUITING	Phase II Dutasteride in Combination With CAB vs CAB in SDC
NCT03614364	PHASE2	UNKNOWN	Combination of Nanoxel and Herzuma in Salivary Duct Carcinoma
NCT04291300	PHASE2	COMPLETED	Lutetium-177-PSMA Radioligand Therapy in Advanced Salivary Gland Cancer Patients
NCT04249947	PHASE1	TERMINATED	P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC)
NCT03319641	Not specified	COMPLETED	PSMA-PET Imaging for Advanced ACC/SDC
NCT04214353	Not specified	UNKNOWN	PSMA-PET Imaging Before and After ADT in Advanced SDC Patients

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
DUTASTERIDE	4	1
TRASTUZUMAB	4	1
RIMIDUCID	2	1